These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11313199)

  • 1. [Combretastatin A4 phosphate].
    Verdier-Pinard P; Lansiaux A; Bailly C
    Bull Cancer; 2001 Mar; 88(3):235-9. PubMed ID: 11313199
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4.
    Aleksandrzak K; McGown AT; Hadfield JA
    Anticancer Drugs; 1998 Jul; 9(6):545-50. PubMed ID: 9877243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional imaging in phase I studies: decorations or decision making?
    Collins JM
    J Clin Oncol; 2003 Aug; 21(15):2807-9. PubMed ID: 12807933
    [No Abstract]   [Full Text] [Related]  

  • 4. Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4.
    Hall JJ; Sriram M; Strecker TE; Tidmore JK; Jelinek CJ; Kumar GD; Hadimani MB; Pettit GR; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5146-9. PubMed ID: 18710804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineoplastic agents 460. Synthesis of combretastatin A-2 prodrugs.
    Pettit GR; Moser BR; Boyd MR; Schmidt JM; Pettit RK; Chapuis JC
    Anticancer Drug Des; 2001; 16(4-5):185-93. PubMed ID: 12049477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combretastatin A4 phosphate: a novel vascular disrupting agent.
    Nagaiah G; Remick SC
    Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.
    McGown AT; Fox BW
    Anticancer Drug Des; 1989 Mar; 3(4):249-54. PubMed ID: 2930627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
    Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
    Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
    Kirwan IG; Loadman PM; Swaine DJ; Anthoney DA; Pettit GR; Lippert JW; Shnyder SD; Cooper PA; Bibby MC
    Clin Cancer Res; 2004 Feb; 10(4):1446-53. PubMed ID: 14977848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combretastatin-based compounds with therapeutic characteristics: a patent review.
    Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
    Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins.
    Medarde M; Ramos AC; Caballero E; Peláez-Lamamié de Clairac R; López JL; Grávalos DG; Feliciano AS
    Bioorg Med Chem Lett; 1999 Aug; 9(16):2303-8. PubMed ID: 10476858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
    Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
    J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2.
    Pettit GR; Quistorf PD; Fry JA; Herald DL; Hamel E; Chapuis JC
    J Nat Prod; 2009 May; 72(5):876-83. PubMed ID: 20161135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism.
    Hori K
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):109-22. PubMed ID: 22101805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity.
    Hatanaka T; Fujita K; Ohsumi K; Nakagawa R; Fukuda Y; Nihei Y; Suga Y; Akiyama Y; Tsuji T
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3371-4. PubMed ID: 9873736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenesis drugs target specific cancers, mechanisms.
    Randal J
    J Natl Cancer Inst; 2000 Apr; 92(7):520-2. PubMed ID: 10749899
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting tumour vasculature: the development of combretastatin A4.
    Griggs J; Metcalfe JC; Hesketh R
    Lancet Oncol; 2001 Feb; 2(2):82-7. PubMed ID: 11905799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue.
    Griggs J; Hesketh R; Smith GA; Brindle KM; Metcalfe JC; Thomas GA; Williams ED
    Br J Cancer; 2001 Mar; 84(6):832-5. PubMed ID: 11259100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oxazole-bridged combretastatin A-4 analogues as potential vascular-disrupting agents.
    Mahal K; Biersack B; Schobert R
    Int J Clin Pharmacol Ther; 2013 Jan; 51(1):41-3. PubMed ID: 23259996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.